The global cardiac biomarkers testing market is anticipated to expand at substantial CAGR of 10.8% during the forecast period, between 2021 and 2028. Cardiac biomarkers are protein particles that are discharged into the blood subsequent to heart stress or heart damage. These biomarker acts as a probable gadget to spot a variety of cardiovascular diseases including myocardial infarction, congestive heart failure, cardiac ischemia, and acute coronary syndrome. The cardiac biomarker tests permit the doctor to determine the danger of a patient related with such diseases.
The biomarkers facilitate the timely recognition of cardiovascular circumstances and assist patients prevent these situations, such as acute coronary syndrome and myocardial infarction. According to World Health Organization (WHO), in the US, approximately 18 million people died from cardiovascular disease. The myocardial infarction is one of the situations that arise due to cardiovascular diseases. This causes major death and morbidity. A timely identification of heart conditions allows doctors to examine the risk of their patients and recommend applicable treatment.
Market Trends, Drivers, Restraints, and Opportunities:
- Rising elderly population and increasing number of patients suffering from chest pain and heart attacks owing to change in lifestyles are anticipated to boost the growth of the global market in the coming years.
- Increasing financial support from private and public organizations for investigation on cardiac biomarkers is projected to drive the market growth in the upcoming years.
- Limited specificity in a few cases and side effects related to cardiac biomarkers such as skeletal muscle wound are likely to hamper the global cardiac biomarkers testing market growth in the coming years.
- Ongoing R&D investment for advanced diagnostic tools can create lucrative opportunities during the forecast period.
Scope of the report:
The report on cardiac biomarkers testing market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
Attributes | Details |
Report Title | Cardiac Biomarkers Testing Market – Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year | 2020 |
Historic Data | 2018 & 2019 |
Forecast Period | 2021–2028 |
Segmentation | Types (Creatine Kinase (CK-MB), Troponins, Myoglobins, Natriuretic Peptides [BNP and NT-proBNP], Ischemia Modified Albumins, and Others), Applications (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others), and Location of Testing (Point-of-care Testing and Laboratory Testing) |
Regional Scope | Asia Pacific, North America, Europe, Latin America, and Middle East & Africa |
Report Coverage | Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities, and revenue forecast |
Key Players Covered in the Report | Abbott Laboratories, Becton, Dickinson and Company, BioMérieux, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Randox Laboratories, Siemens Healthineers, and Thermo Fisher Scientific |
Cardiac Biomarkers Testing Market Segment Insights:
Troponins segment is is projected to hold significant market share
In the terms of types, the market can be divided into creatine kinase (CK-MB), troponins, myoglobin, natriuretic peptides; ischemia modified albumins, and others. The natriuretic peptides are further divided into BNP and NT-proBNP. The troponins segment held a major share in 2020 and is expected to continue its domination throughout the forecast period owing to rising occurrence of myocardium infarction and acute coronary syndrome, which increases the number of congestive heart failure cases all over the globe.
Myocardial Infarction to hold substantial share in the global market
Based on applications, the cardiac biomarkers testing market can be fragmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. The myocardial infarction segment is projected to hold a significant share in the market owing to rising prevalence of cardiovascular diseases and increased demand for biomarker tests for early detection of heart failure.
Laboratory testing segment to dominate the market
On the basis of location of testing, the cardiac biomarkers testing market can be divided into point-of-care testing and laboratory testing. The laboratory testing segment is anticipated to lead the global market due to the increasing disposable incomes, healthcare expenditure, healthcare infrastructure, and government initiatives for preventing heart attacks
North America expected to grow at a significant rate in the forecasted period
In terms of regions, the cardiac biomarkers testing market can be divided into Asia pacific, North America, Europe, Latin America, and Middle East & Africa. The North America is expected to hold a majority share in the global market owing to high expenses on research and development, presence of key players and their product accessibility, and well recognized healthcare infrastructure in the region.
Segments
By Types
- Creatine Kinase (CK-MB)
- Troponins
- Myoglobins
- Natriuretic Peptides
- Ischemia Modified Albumins
- Others
By Applications
- Myocardial Infarction
- Congestive Heart Failure
- Acute Coronary Syndrome
- Atherosclerosis
- Others
By Location of Testing
- Point-of-care Testing
- Laboratory Testing
By Regions
- Asia Pacific
- North America
- Europe
- Latin America
- Middle East & Africa
By Key Players
- Abbott Laboratories
- Becton
- Dickinson and Company
- BioMérieux
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- F. Hoffmann-La Roche AG
- Randox Laboratories
- Siemens Healthineers
- Thermo Fisher Scientific
Competitive Landscape
Key players in the cardiac biomarkers testing market include Abbott Laboratories, Becton, Dickinson and Company, BioMérieux, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Randox Laboratories, Siemens Healthineers, and Thermo Fisher Scientific. These players engage in mergers & acquisitions, collaborations, agreements, and partnerships to strengthen their geographical presence.